Analyst Report: RVTY

1. EXECUTIVE SUMMARY

Revvity rose 7.84% to $163.48 on Tuesday 3 November 2026, the day it reported third-quarter results before the open. According to the Motley Fool transcript and Pomegra, adjusted EPS of $1.37 and revenue of about $729m beat consensus of roughly $1.30 and $695m, and management raised full-year adjusted EPS guidance to $5.40–$5.45. The shares had fallen 5.30% on 30 October and 3.44% on 2 November with no sourced cause, so the rally recovered most of those losses, and the intraday high of $171.74 set a new 52-week high. The stock trades at 27.6 times forward earnings after a 66.97% gain this year, which leaves the valuation dependent on the guidance being delivered. One data conflict applies: the site's EPS and revenue estimates ($1.61 and $759.52m) differ from the consensus the sources cite, so the beat is described here using the sourced figures.

2. THE CATALYST

Revvity released third-quarter 2026 results before the open on 3 November. TradingPedia reported that shares rose 8.8% in pre-open trading, and the session closed up 7.84% on volume of 3,372,300, which is 1.72 times the 50-session average.

Guidance was raised. Adjusted EPS is now $5.40–$5.45, which management describes as 12% growth. Organic growth is expected at about 5%, up from 4%–5%. Revenue guidance is about $2.86bn, and the full-year operating margin target of 28.8% was raised for the third consecutive quarter (Motley Fool transcript; Pomegra). The guidance includes about 75 basis points from the ACD/Labs acquisition and about 50 basis points from foreign exchange.

Evercore ISI raised its price target to $180 from $165 on the same day (CNN/TipRanks); the rating was not confirmed in the snippet. A TradingView headline cited a 12-month target of $150.43, but only the headline was read, so the firm and the prior target are unconfirmed.

3. COMPANY PROFILE

Revvity is a healthcare company in diagnostics and research, with a market cap of $18.24bn. It sells instruments, reagents, software, subscriptions and services for life sciences research, and assay platforms for diagnostics, including newborn and early-childhood screening and infectious disease testing. Peers in the facts panel are drawn from health care equipment (MDT, ISRG, ABT, BSX, SYK, DXCM).

In the third quarter, Life Sciences organic growth was 9%. Reagents grew high single digits and software grew in the upper teens. Diagnostics grew 5% organically, in line with management's expectations. Pharma and biotech sales grew 10%–12%, Europe and the Americas each grew at double-digit rates, and high content screening accelerated with a larger backlog (Motley Fool transcript). Diagnostics operating margin was 29.9% as reported, which management said is over 600 basis points of expansion excluding the China immunodiagnostics business. CEO Prahlad Singh and CFO Maxwell Krakowiak presented the results.

Reported revenue growth was 4% against 7% organic, so the two measures should be kept apart. The company declared a $0.07 quarterly dividend on 30 October, with a record date of 22 January 2027 and payment on 12 February 2027 (Business Wire via Yahoo Finance).

4. DEEP DIVE ANALYSIS

The fundamentals support a positive reaction. Organic growth of 7% beat management's own mid-single-digit expectation, and the margin outlook has risen three quarters running. Earnings guidance implies 12% growth, and cash generation of $152m with leverage at 2.3x gives balance sheet room. The Motley Fool transcript summary attributes Life Sciences strength to AI-driven demand in screening and detection.

The size of the move needs context. The shares closed at $165.78 on 29 October, so the 3 November close of $163.48 sits 1.39% below that level. The earlier pullback of 5.30% and 3.44% over two sessions has no sourced cause (GuruFocus's 30 October piece was a valuation note, and the dividend news came after that close). The results day therefore reversed an unexplained drop and added little beyond the prior high close. Inference: some of the earlier selling may have been positioning ahead of the report, though no source says so.

Peers do not explain the move. MDT fell 0.41%, ISRG rose 0.89%, ABT fell 0.69%, BSX fell 1.85%, SYK rose 1.22% and DXCM fell 2.11%, while the S&P 500 rose 0.36%. TradingPedia described the advance as tied to Revvity's own developments.

Comparable episodes: the stock gained 6.03% on 24 September with no sourced cause (StockAnalysis), and on 6 October it hit an intraday high of $166.25 before closing down 2.58% (MacroAxis). The 3 November session is the clearest results-driven move in the sources this year.

Bull case: guidance has risen three quarters in a row, Life Sciences demand is broad across regions and customer types, and analysts have been lifting targets (TD Cowen to $175 on 13 October, Evercore to $180, BofA to $165 and Barclays to $160 on 7 October, KeyBanc to $165 on 4 September).

Bear case: the stock trades at 27.6 times forward earnings and 78.2 times trailing earnings, and has gained 40.97% over 60 sessions. The consensus rating was Hold across 21 analysts as of 8 October (TradingView), with an average target of $142.93 then, below the current price. Diagnostics growth of 5% is modest, and the full-year margin includes acquisition and currency contributions. The sources disagree on the average target ($124.43 at Cerbat Gem, which looks stale, $142.93 at TradingView and $147.53 in an undated Yahoo snapshot).

5. TECHNICAL SNAPSHOT

The close of $163.48 sits above the 50-day average of $145.78 and the 200-day average of $112.21, and 101.5% above the 52-week low of $81.13 set on 29 April. The session high of $171.74 is the new 52-week high, and the close finished $8.26 below it, which shows sellers met the early spike. The nearest support is the prior close of $157.00 on 30 October, and the nearest resistance is $165.78 from 29 October, with $171.74 above that. Volume of 3,372,300 was the highest in the table and 1.72 times the 50-session average.

6. RISK FACTORS

• Valuation: the forward multiple of 27.6 leaves little room for a miss against the raised guidance.
• Guidance quality: acquisition and currency add about 125 basis points to the outlook, and Diagnostics growth of 5% is in line rather than ahead.
• Unexplained volatility: the two sessions before results fell by a combined 8.55% from the 29 October close of $165.78 without a sourced reason.
• Data conflicts: consensus estimates differ between the site and the sources, and a Yahoo snapshot lists GAAP profit of 56 cents per share against $1.37 adjusted, although that text was truncated and is unverified. The Business Wire release and the Evercore note were not read.
• Integration: Revvity agreed to acquire Human Cell Design in early September; closing status is not sourced.

Dated events: the dividend record date is 22 January 2027 and payment is 12 February 2027. The fourth-quarter results date is not sourced.

7. ACTIONABLE OUTLOOK

Short term (1-2 weeks): the stock holds the post-results gap, with $165.78 as the level to clear and $157.00 as the first support. More target increases following the Evercore move are likely, and the 3 November volume spike makes a retest of the prior range part of the near-term picture.

Medium term (1-3 months): the path depends on whether analysts move the Hold consensus toward Buy. Their average target sat near $143 in early October and has been rising, with several targets now above the current price. Delivery against the 28.8% margin target and the 5% organic growth outlook will set the tone.

Long term: the thesis of life sciences recovery plus margin expansion has strengthened on this report, since guidance rose again and cash generation and leverage improved. The valuation now prices much of that progress, and the 66.97% year-to-date gain leaves less margin for error. This is analysis only and not personal financial advice.